

Hani Gabra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3986489/publications.pdf>

Version: 2024-02-01

68
papers

6,137
citations

159358

30
h-index

106150

65
g-index

69
all docs

69
docs citations

69
times ranked

11066
citing authors

#	ARTICLE	IF	CITATIONS
1	Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG) Tj ETQq1 1 0.784314 rgBT /Overbo 541-553.	6.3	75
2	Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers. Cancer Gene Therapy, 2021, 28, 18-26.	2.2	6
3	A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer. Clinical Cancer Research, 2021, 27, 3028-3038.	3.2	4
4	Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma. Nature Communications, 2021, 12, 1454.	5.8	20
5	The association between obesity and weight loss after bariatric surgery on the vaginal microbiota. Microbiome, 2021, 9, 124.	4.9	14
6	Oncologist-led BRCA "mainstreaming"™ in the ovarian cancer clinic: A study of 255 patients and its impact on their management. Scientific Reports, 2020, 10, 3390.	1.6	34
7	[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1239-1251.	3.3	12
8	Proteomic analysis of malignant and benign endometrium according to obesity and insulin-resistance status using Reverse Phase Protein Array. Translational Research, 2020, 218, 57-72.	2.2	7
9	Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions. Nature Communications, 2019, 10, 3134.	5.8	9
10	<p>Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification</p>. Journal of Pain Research, 2019, Volume 12, 2039-2052.	0.8	58
11	Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome. Annals of Surgical Oncology, 2019, 26, 2943-2951.	0.7	54
12	Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. Radiology, 2019, 293, 374-383.	3.6	25
13	<p>Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population</p>. Hepatic Medicine: Evidence and Research, 2019, Volume 11, 47-67.	0.9	10
14	A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. Nature Communications, 2019, 10, 764.	5.8	130
15	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCG phase 3 randomised controlled trial. Lancet, The, 2019, 394, 2084-2095.	6.3	142
16	Risk factors for endometrial cancer: An umbrella review of the literature. International Journal of Cancer, 2019, 145, 1719-1730.	2.3	290
17	Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells. Cancer Biology and Therapy, 2019, 20, 21-30.	1.5	14
18	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. Neoplasia, 2018, 20, 280-288.	2.3	23

#	ARTICLE	IF	CITATIONS
19	Clinical value of bioelectrical properties of cancerous tissue in advanced epithelial ovarian cancer patients. <i>Scientific Reports</i> , 2018, 8, 14695.	1.6	7
20	Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study. <i>British Journal of Cancer</i> , 2018, 119, 815-822.	2.9	35
21	Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).. <i>British Journal of Cancer</i> , 2018, 119, 330-338.	2.9	13
22	Biomarker Assessment of HR Deficiency, Tumor <i>BRCA1/2</i> Mutations, and <i>CCNE1</i> Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy. <i>Molecular Cancer Research</i> , 2018, 16, 1103-1111.	1.5	83
23	Copy number signatures and mutational processes in ovarian carcinoma. <i>Nature Genetics</i> , 2018, 50, 1262-1270.	9.4	320
24	The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. <i>EMBO Reports</i> , 2018, 19, .	2.0	30
25	Anti-tumorigenic and Platinum-Sensitizing Effects of Apolipoprotein A1 and Apolipoprotein A1 Mimetic Peptides in Ovarian Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 1524.	1.6	18
26	Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective. <i>Journal of Clinical Oncology</i> , 2017, 35, 587-590.	0.8	38
27	British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 213, 123-139.	0.5	64
28	Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapyâ€“Innovative Models Prolong Survival (OCTIPS) Consortium. <i>European Journal of Cancer</i> , 2017, 79, 214-225.	1.3	29
29	Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. <i>British Journal of Cancer</i> , 2017, 116, 1287-1293.	2.9	22
30	Endocrine therapy in epithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 109-117.	1.1	41
31	A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7621-7632.	3.2	31
32	WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response. <i>Cell Death and Disease</i> , 2017, 8, e2955-e2955.	2.7	37
33	The Tumor-Suppressor Protein OPCML Potentiates Antiâ€“EGFR- and Antiâ€“HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2246-2256.	1.9	24
34	Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2213-2222.	3.2	83
35	Adiposity and cancer at major anatomical sites: umbrella review of the literature. <i>BMJ: British Medical Journal</i> , 2017, 356, j477.	2.4	539
36	Obesity and gynaecological and obstetric conditions: umbrella review of the literature. <i>BMJ: British Medical Journal</i> , 2017, 359, j4511.	2.4	107

#	ARTICLE	IF	CITATIONS
37	Integrative Analysis of Subcellular Quantitative Proteomics Studies Reveals Functional Cytoskeleton Membrane-Lipid Raft Interactions in Cancer. <i>Journal of Proteome Research</i> , 2016, 15, 3451-3462.	1.8	15
38	TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition. <i>Cell Death and Disease</i> , 2016, 7, e2522-e2522.	2.7	40
39	Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer. <i>International Journal of Oncology</i> , 2016, 49, 1651-1665.	1.4	34
40	The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. <i>Science Signaling</i> , 2016, 9, ra97.	1.6	105
41	Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy. <i>Oncotarget</i> , 2016, 7, 7216-7226.	0.8	29
42	A phase Ib study of NUC1031 and carboplatin for patients with recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5565-5565.	0.8	2
43	The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma. <i>Oncotarget</i> , 2015, 6, 31593-31603.	0.8	39
44	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , 2015, 521, 489-494.	13.7	1,206
45	Dose-Finding Quantitative ¹⁸ F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1828-1835.	2.8	24
46	The Next Steps in Improving the Outcomes of Advanced Ovarian Cancer. <i>Women's Health</i> , 2015, 11, 355-367.	0.7	8
47	Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. <i>European Journal of Cancer</i> , 2015, 51, 1978-1988.	1.3	44
48	A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway. <i>Oncotarget</i> , 2015, 6, 41736-41749.	0.8	22
49	The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future. <i>British Medical Bulletin</i> , 2014, 112, 57-69.	2.7	19
50	Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures. <i>Modern Pathology</i> , 2014, 27, 433-442.	2.9	13
51	ProGem1: A phase I/II study of a first-in-class nucleotide, Acelarin, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2531-2531.	0.8	5
52	Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance. <i>Cancer Treatment Reviews</i> , 2013, 39, 153-160.	3.4	53
53	ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2576-2576.	0.8	7
54	The OPCML Tumor Suppressor Functions as a Cell Surface Repressor-Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer. <i>Cancer Discovery</i> , 2012, 2, 156-171.	7.7	50

#	ARTICLE	IF	CITATIONS
55	Evaluation of 2-Deoxy-2-[18F]Fluoro-D-glucose- and 3-Deoxy-3-[18F]Fluorothymidine-Positron Emission Tomography as Biomarkers of Therapy Response in Platinum-Resistant Ovarian Cancer. <i>Molecular Imaging and Biology</i> , 2012, 14, 753-761.	1.3	23
56	Epithelial Ovarian Cancer. , 2012, , 760-775.		2
57	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011, 11, 719-725.	12.8	1,084
58	Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3798-3804.	0.8	203
59	HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer. <i>Cancer Research</i> , 2011, 71, 4412-4422.	0.4	159
60	Targeting the AKT Pathway in Ovarian Cancer. , 2011, , 73-94.		3
61	Targeting locoregional peritoneal dissemination in ovarian cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2009, 4, 133-147.	0.4	7
62	Endometrioid epithelial ovarian cancer. <i>Cancer</i> , 2008, 112, 2211-2220.	2.0	89
63	The IgLON Family in Epithelial Ovarian Cancer: Expression Profiles and Clinicopathologic Correlates. <i>Clinical Cancer Research</i> , 2005, 11, 5764-5768.	3.2	49
64	Carcinosarcoma of the ovary. <i>Cancer</i> , 2004, 100, 2148-2153.	2.0	133
65	OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. <i>Nature Genetics</i> , 2003, 34, 337-343.	9.4	169
66	Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression. <i>Cancer Research</i> , 2003, 63, 8648-55.	0.4	29
67	Current clinical trials in ovarian cancer. , 0, , 205-222.		0
68	Epithelial Ovarian Cancer. , 0, , 625-635.		1